Endari - Us was Emmaus Life Sciences’s largest product and service line in fiscal 2025, bringing in $18.10M of $24.91M (73%).
| Product and Service | FY 2017 | FY 2018 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Endari | $35.71M | — | — | — | ||||||
| Endari - Us | — | $44.00M | $26.96M | $18.10M | ||||||
| Endari - International | — | $13.93M | $5.34M | $6.36M | ||||||
| Telepsychiatry Services | — | — | — | — | ||||||
| Other | $1.07M | $1.27M | $1.01M | $450.00K | ||||||
| Neurometric Services | — | — | — | — | ||||||
| Total | $36.78M | $59.19M | $33.31M | $24.91M |
Emmaus Life Sciences brought in $24.91M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 25.2% from $33.31M in fiscal 2024. Endari - Us was the largest at $18.10M (72.7%), ahead of Endari - International at $6.36M (25.5%) and Other at $450.00K (1.8%).
Compared with fiscal 2024, Endari - International grew 19.1% to $6.36M, while Endari - Us fell 32.9% to $18.10M.
Emmaus Life Sciences began breaking out Endari - Us in fiscal 2023 and Endari - International in fiscal 2023. Emmaus Life Sciences stopped reporting Endari as a separate line after fiscal 2022, when it brought in $35.71M.
Previously Reported was Emmaus Life Sciences’s largest revenue line in fiscal 2019, bringing in $12.17M of $11.52M (106%).
| Restatement | FY 2018 | FY 2019 |
|---|---|---|
| Previously Reported | $30.15M | $12.17M |
| Adjustments | $2.76M | -$648.00K |
| Total | $32.92M | $11.52M |
Emmaus Life Sciences brought in $11.52M from its two revenue lines in fiscal 2019, the year ended September 30, 2019. That was down 65.0% from $32.92M in fiscal 2018. Previously Reported was the largest at $12.17M (105.6%).
The total is net of Adjustments, which took $648.00K off revenue in fiscal 2019.
Emmaus Life Sciences (EMMA) reports its revenue by product and service and by restatement. In fiscal 2025, Endari - Us was its largest product and service line, bringing in $18.10M (72.7% of the total), followed by Endari - International at $6.36M (25.5%).
Endari - Us was Emmaus Life Sciences' largest product and service line in fiscal 2025, bringing in $18.10M, or 72.7% of the $24.91M total across its three product and service lines.
Previously Reported was Emmaus Life Sciences' largest revenue line in fiscal 2019, bringing in $12.17M, or 105.6% of the $11.52M total across its two revenue lines.
Endari - International grew faster than Endari - Us in fiscal 2025, up 19.1% from $5.34M to $6.36M. Endari - Us fell 32.9% to $18.10M.
Every figure comes from Emmaus Life Sciences' annual financial filings, as reported. Each line keeps the name Emmaus Life Sciences gives it, and years follow its fiscal calendar.
Emmaus Life Sciences' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.